Fraiser Kansteiner

1 week ago | fiercepharma.com | Fraiser Kansteiner

Following HHS secretary Robert F. Kennedy Jr.’s decision last week to purge the CDC’s Advisory Committee on Immunization Practices (ACIP) and appoint his own replacements, the 17 ousted experts are hitting back at the arguments behind the cull.

1 week ago | fiercepharma.com | Fraiser Kansteiner

With the industry in a holding pattern, President Donald Trump is again beating the drum for pharmaceutical import tariffs—though the exact nature and timing of their implementation remains unclear as ever. U.S. trade duties on pharmaceutical products are coming “very soon,” Trump told reporters aboard Air Force One on Tuesday morning. The President made the remarks during a return trip from the G7 meeting in Canada, Reuters reports. "We're going to be doing pharmaceuticals very soon.

1 week ago | fiercepharma.com | Fraiser Kansteiner

Amid a spate of high-profile investments in U.S. pharmaceutical production, two contract manufacturers are getting in on the action with an emphasis on biologic drugs. First, active pharmaceutical ingredient specialist Veranova is plugging roughly $20 million more into its campus in Devens, Massachusetts, to establish new bioconjugation development and production capacity at the site.

1 week ago | fiercepharma.com | Fraiser Kansteiner

Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug to make its mark. Next up, the complement inhibitor—which AZ inherited in its $39 billion Alexion purchase—could help address a potentially life-threatening transplant complication without any targeted treatments, according to early phase 3 data from a single-arm trial released over the weekend.

1 week ago | fiercepharma.com | Fraiser Kansteiner |Zoey Becker |Eric Sagonowsky |Angus Liu